Flavanone-rich citrus beverages counteract the transient decline in postprandial endothelial function in humans: a randomised, controlled, double-masked, cross-over intervention study

Catarina Rendeiro1, Honglin Dong1, Caroline Saunders2, Laura Harkness3, Melvin Blaze4, Yanpeng Hou4, Ronald L. Belanger2, Giulia Corona1§, Julie A. Lovegrove1 and Jeremy P. E. Spencer1*

1Department of Food and Nutritional Sciences, School of Chemistry, Food and Pharmacy, University of Reading, PO Box 226, Reading RG2 6AP, UK
2PepsiCo R+D Nutrition, PepsiCo Inc., Reading RG2 6UW, UK
3Global R+D Nutrition, PepsiCo Inc., Valhalla, NY 10595, USA
4PepsiCo R+D Biological & Discovery Analytics, PepsiCo Inc., New Haven, CT 06511, USA

Abstract

Specific flavonoid-rich foods/beverages are reported to exert positive effects on vascular function; however, data relating to effects in the postprandial state are limited. The present study investigated the postprandial, time-dependent (0–7 h) impact of citrus flavanone intake on vascular function. An acute, randomised, controlled, double-masked, cross-over intervention study was conducted by including middle-aged healthy men (30–65 years, n = 28) to assess the impact of flavanone intake (orange juice: 128.9 mg; flavanone-rich orange juice: 272.1 mg; homogenised whole orange: 452.8 mg; isoenergetic control: 0 mg flavanones) on postprandial (double meal delivering a total of 81 g of fat) endothelial function. Endothelial function was assessed by flow-mediated dilatation (FMD) of the brachial artery at 0, 2, 5 and 7 h. Plasma levels of naringenin/hesperetin metabolites (sulphates and glucuronides) and nitric oxide species were also measured. All flavanone interventions were effective at attenuating transient impairments in FMD induced by the double meal (7 h post intake; P < 0.05), but no dose–response effects were observed. The effects on FMD coincided with the peak of naringenin/hesperetin metabolites in circulation (7 h) and sustained levels of plasma nitrite. In summary, citrus flavanones are effective at counteracting the negative impact of a sequential double meal on human vascular function, potentially through the actions of flavanones metabolites on nitric oxide.

Key words: Citrus flavanones: Endothelial function: High-fat meals: Nitric oxide: Postprandial state

A transient impairment in vascular function is known to occur in the postprandial or fed state(11–14) and is widely believed to impact on endothelial dysfunction and lifetime CVD risk(5–8). In particular, endothelial function has been shown to be transiently impaired (2–8 h) following ingestion of moderate- to high-fat meals (36–80 g of fat)(9–13), potentially driven by hyperglycaemia and hypertriglyceridaemia, which occurs during the postprandial state(14,15). Observational data have highlighted that the consumption of diets rich in flavonoids might lead to an improved cardiovascular prognosis(16–20). Indeed, flavonoid-rich foods and beverages are well reported to improve endothelial function acutely in humans both at(21–24) short term(25–27) and long term(28–31). However, most of the acute interventions were undertaken with volunteers in the fasted state, which is considered less representative of the free-living state, whereas data relating to flavonoid potential to ameliorate acutely postprandial endothelial impairments are more scarce(32–34).

Although the precise mechanisms by which absorbed flavonoids and their circulating metabolites mediate beneficial vascular effects remain unclear, there is evidence to suggest that the modulation of circulating nitric oxide (NO) levels might be involved(22–24,35–38). Notably, flavanol-rich cocoa has been consistently shown to improve endothelium-dependent vasodilation in healthy individuals(24,27,31,39,40), smokers(23,26), patients with...
coronary artery disease\(^{(41)}\), hypertension\(^{(42)}\) or diabetes\(^{(43)}\). In particular, acute vascular improvements have been shown to coincide with the appearance of flavanol metabolites in the circulation and with peak plasma NO levels\(^{(23,24,26,42)}\). Furthermore, flavanol-induced improvements in vascular function are inhibited following co-administration of an endothelial nitric oxide synthase (eNOS) inhibitor, suggesting a cause-and-effect relationship between flavonoid intake, plasma NO levels and vascular function\(^{(23,44)}\). Although less studied, flavanones from citrus fruits have also been shown to exert beneficial effects on human vascular function\(^{(20,44)}\). In particular, chronic interventions with orange juice, or the pure flavanone hesperidin, resulted in a decrease in blood pressure in overweight volunteers and acute (6 h) improvements in micro-vascular reactivity\(^{(45)}\). Short-term intake of pure hesperidin also resulted in significant improvements in endothelial function (as measured by brachial artery flow-mediated dilation (FMD)) in volunteers with the metabolic syndrome\(^{(46)}\).

In the present study, we assessed the impact of an acute intervention with increasing doses of orange flavanones (sourced from differently processed orange beverages) on human vascular function in the postprandial state. A sequential double meal (breakfast and lunch, delivering a total of 81 g of fat) was used to simulate the fed state and investigate the postprandial time-dependent effects of flavanone intake on endothelial function as measured by brachial artery FMD.

**Methods**

**Ethics**

The clinical trial was registered at clinicaltrials.gov (NCT01963416) and conducted according to the Declaration of Helsinki following Good Clinical Practice. It was approved for conduct by the University of Reading’s Research Ethical Committee (ethics reference no. 12/06). All volunteers signed an informed consent form before commencing the study.

**Intervention study volunteers**

Volunteers were recruited from the University of Reading and surrounding areas using the Hugh Sinclair Unit volunteers’ database, poster advertisements within the university and local community via local websites (April–December 2012). In total, fifty-nine, healthy, male volunteers, aged 30–65 years, were assessed for screening and were selected according to the following inclusion criteria: (1) fasting lipids in the upper half of the normal range (TAG 0–8–3.2 mmol/l and total cholesterol 60–80 mmol/l) or BMI 25–32 kg/m\(^2\); (2) non-smoker; (3) non-diabetic (diagnosed or fasting glucose >7 mmol/l) with no endocrine disorders; (4) Hb and liver enzyme levels within the normal range; (5) not having suffered a myocardial infarction/stroke in the past 12 months; (6) not suffering from renal or bowel diseases or having a history of cholestatic liver or pancreatitis; (7) not on drug treatment for hyperlipidaemia, hypertension, inflammation or hyper-coagulation; (8) not taking any fish oil, fatty acid or vitamin and mineral supplements; (9) no history of alcohol misuse; (10) not planning weight loss or on a weight-reducing regimen; (11) not taken antibiotics during the 6 months before the study; and (12) not being able to consume the study meals. Those selected for the study were instructed not to alter their usual dietary or fluid intakes. Volunteers were asked to refrain from the following for 24 h before and during the study: (1) consumption of polyphenol-rich foods including fruits (including citrus fruits), vegetables, cocoa, chocolate, coffee, tea, fruit juices and wine; (2) consumption of foods rich in nitrates, including beetroot, spinach, lettuce, rocket, celery, parsley and cabbage (defined as containing >50 mg nitrates/100 g fresh weight\(^{(47)}\); (3) performing rigorous exercises; and (4) consuming any alcoholic beverage. Volunteers were further asked to fast for 12 h before each study visit, and during that period they were to only consume the low-nitrate water provided. The same standard meal, low in polyphenols and nitrates, was also provided for dinner for the day before each visit. Written informed consent was obtained from all eligible volunteers before their participation in the study.

**Study design**

The study design was an acute, randomised, placebo-controlled, double-masked, postprandial, cross-over study (Fig. 1). After the initial screening visit to assess the eligibility of volunteers for participation, volunteers were enrolled into the study (by researchers C. R. and H. D.) and visited the Hugh Sinclair Unit at the University of Reading on four separate occasions separated by a 2-week period (June–December 2012). Volunteers were asked to consume either a (a) control drink (C), (b) orange juice beverage (OJ), (c) flavanone-rich orange juice (FROJ) or (d) whole orange beverage (WO), together with a high-fat breakfast (at baseline, \(t=0\) h), followed by a medium-fat lunch (\(t=5.5\) h). H. D. assigned participants to the three-digit coded drink interventions for their four visits according to a random allocation sequence generated by a third party. Details on flavonoid composition of the interventions, as well as micronutrient and macronutrient compositions, can be found on Table 1. Compliance to a 24-h low-polyphenol intake period and 12 h of fasting was monitored using a 24-h dietary recall conducted.
during each study visit. On each visit day, volunteers rested for 30 min in a quiet, temperature-controlled room before they were cannulated by a qualified research nurse; blood samples were collected in the fasted state (0 h) and at 2, 5, 7 and 24 h after consumption of each intervention drink. FMD of the brachial artery was the primary outcome and it was measured at 0, 2, 5 and 7 h after consumption. Secondary outcomes of the study included systolic and diastolic blood pressures (0, 2, 5, 7 h), plasma flavanone levels (0, 2, 5, 7, 24 h) and NO plasma levels (0, 2, 5, 7 h). After baseline measurements were obtained, the high-fat breakfast (Table 2) was consumed with one of the clinical products (C, OJ, FROJ, WO). Volunteers were asked to consume the intervention drink and the high-fat meal within 10–15 min. At 5.5 h from baseline, a medium-fat lunch was provided (Table 2). The last measurement of the day was performed at 7 h, and the volunteers were asked to return to the clinical unit the following morning to provide a 24-h blood sample (fasted). From 7 to 24 h, volunteers were asked to consume the free polyphenol dinner provided by the research team and to continue on the low-polyphenol diet, as well as refrain from exercise and alcohol consumption. Blood samples for flavonoid analysis were collected in EDTA-containing tubes (Greiner Bio-One Ltd), immediately centrifuged for 15 min at 4°C (4000 g), and the plasma samples were spiked with formic acid (1.5% of a 50% water solution) and ascorbic acid (5% of a 10 mM solution) and stored at −80°C. Blood samples for NO analysis were collected in heparin-containing tubes, immediately (within 3 min of collection) centrifuged for 15 min at 4°C (4000 g), and plasma was rapidly collected, aliquoted and stored at −80°C to reduce inactivation of nitroso species.

### Sequential double meal

The sequential double-meal protocol was based on the department’s extensive experience on postprandial studies, which have been collated into the Dietary Studies: Reading Unilever Postprandial Trials (DISRUPT) database(48). It consisted of two meals: (1) high-fat breakfast (51 g fat; 14 g protein; 64 g carbohydrates; 3251 kJ (777 kcal)) administrated with the intervention drink and (2) medium-fat lunch (30 g fat; 15 g protein; 80 g carbohydrates; 2628 kJ (628 kcal)) (Table 2) administrated 5.5 h after the intervention drink. The high-fat meal consisted of two butter croissants (47 g of fat) and 5 g of butter (4 g of fat). The medium-fat meal consisted of two slices of white bread (2 g of fat), 42 g of Philadelphia soft cheese (15 g of fat), a small bag of salted crisps (9 g of fat) and two shortbread biscuits (6 g of fat) (Table 2). The volunteers were asked to consume meals within 10–15 min.

### Flavanones and endothelial function

The sequential double-meal protocol was based on the department’s extensive experience on postprandial studies, which have been collated into the Dietary Studies: Reading Unilever Postprandial Trials (DISRUPT) database(48). It consisted of two meals: (1) high-fat breakfast (51 g fat; 14 g protein; 64 g carbohydrates; 3251 kJ (777 kcal)) administrated with the intervention drink and (2) medium-fat lunch (30 g fat; 15 g protein; 80 g carbohydrates; 2628 kJ (628 kcal)) (Table 2) administrated 5.5 h after the intervention drink. The high-fat meal consisted of two butter croissants (47 g of fat) and 5 g of butter (4 g of fat). The medium-fat meal consisted of two slices of white bread (2 g of fat), 42 g of Philadelphia soft cheese (15 g of fat), a small bag of salted crisps (9 g of fat) and two shortbread biscuits (6 g of fat) (Table 2). The volunteers were asked to consume meals within 10–15 min.

### Flavanone-containing interventions

The preparations of the intervention drinks were carried out according to good manufacturing practice as described in hazard analysis and critical control points (HACCP). The control (C) drink was matched for sugars found in the orange beverages, and 0.67% citric acid and orange flavouring were added to enhance flavour. The levels of total β-carotenes present in the flavanone treatments were considered negligible (approximately 0.25 mg; 2 relative standard deviation of the measurement (2-RSD): 15%) with regard to endothelial function effects, with a 15-mg dose (6 weeks intervention, in combination with 150 mg of vitamin C) resulting in no significant changes on endothelial biomarkers(49) (Table 1). The levels of folate present (approximately 60 μg; 2-RSD: 16%) can also be considered insignificant with regard to its potential to impact on endothelial function; folate has been shown to drive small improvements in endothelial function only in long-term interventions (1–4 months) with at least 5000–10 000 μg/d of folate, but not with lower doses in the ranges of 400–800 μg/d(50).

### Table 1. Macronutrient composition of double-meal protocol

<table>
<thead>
<tr>
<th>Foods</th>
<th>Fat (g)</th>
<th>Protein (g)</th>
<th>Carbohydrates (g)</th>
<th>Energy (kJ)</th>
<th>Energy (kcal)</th>
</tr>
</thead>
<tbody>
<tr>
<td>High-fat breakfast</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Butter croissant (2x)</td>
<td>47</td>
<td>14</td>
<td>64</td>
<td>3096</td>
<td>740</td>
</tr>
<tr>
<td>Butter (5 g)</td>
<td>4</td>
<td>N/A</td>
<td>N/A</td>
<td>159</td>
<td>37</td>
</tr>
<tr>
<td>Total</td>
<td>51</td>
<td>14</td>
<td>64</td>
<td>3251</td>
<td>777</td>
</tr>
<tr>
<td>Medium-fat lunch</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 slices of sliced white bread (108 g)</td>
<td>2</td>
<td>8.5</td>
<td>50</td>
<td>992</td>
<td>237</td>
</tr>
<tr>
<td>Philadelphia soft cheese (42 g)</td>
<td>13</td>
<td>3.6</td>
<td>N/A</td>
<td>548</td>
<td>131</td>
</tr>
<tr>
<td>Crisps (25 g)</td>
<td>9</td>
<td>1.5</td>
<td>13</td>
<td>556</td>
<td>133</td>
</tr>
<tr>
<td>Shortbread biscuit (22 g)</td>
<td>6</td>
<td>1.4</td>
<td>16</td>
<td>521</td>
<td>127</td>
</tr>
<tr>
<td>Total</td>
<td>30</td>
<td>15</td>
<td>80</td>
<td>2628</td>
<td>628</td>
</tr>
</tbody>
</table>
FMD response was calculated as relative diastolic diameter change from baseline as compared with peak diastolic diameter. A total of twenty-eight volunteers were analysed for their FMD response. Data from eight volunteers were not analysed or were excluded because of the following reasons: (i) measurement of FMD from the non-dominant arm (rather than dominant) due to limitations with blood collection (n 2); (ii) absence of FMD response (n 3); and (iii) technical problems during recording of ultrasound FMD measurements rendered non-analysable data (n 3).

Blood pressure

Systolic and diastolic blood pressures were measured using an Omron MX2 automatic digital upper-arm blood pressure monitor (Omron Healthcare UK Ltd). All measurements were taken according to standard practice and by a qualified research nurse, before and following each intervention period. Before starting blood pressure measurements, the volunteers were seated or were laying down quietly for at least 20 min. Measurements were taken in the right arm, before FMD procedure for each time point. The subject's right arm was allowed to rest on a pillow (on a side table positioned at heart level) and was slightly flexed with the palm facing upward. Volunteers were asked to refrain from speaking during blood pressure measurements. The measurements were repeated three times, and blood pressure was considered as the average of these measurements.

Plasma flavanone analysis

Blood samples were collected in EDTA-containing tubes and centrifuged at 4°C for 10–15 min at 4000 × g. Formic acid (1.5% of a 50% solution) and ascorbic acid (5% of a 10-mM solution prepared fresh everyday) were added to the plasma samples to preserve flavanones before freezing at –80°C. A subset of twenty volunteers was selected randomly for analysis of flavanone content. A high throughput analytical method using UHPLC-MS/MS was developed and validated to measure simultaneously naringenin and hesperetin in human plasma. Enzymatic hydrolysis and methanol extraction were applied as described earlier 520 with modifications to accommodate in situ monitoring of enzyme efficiency and automated sample preparation using a Hamilton Microlab Star liquid handling system (Hamilton). Plasma samples (45 litres) were incubated after addition of β-glucuronidase type VII-A (Sigma) and sulfatase type H-5 (Sigma) for 90 and 60 min at 37°C, respectively. To monitor enzyme activity, every individual sample was spiked with a known concentration of phenolphthalein glucuronide and potassium 4-nitrophenyl sulfate (Sigma) as enzyme substrates in addition to caffeine-(trimethyl-d9) (Sigma) as IS before incubation. The enzyme-hydrolysed samples were subsequently extracted with methanol and centrifuged. The supernatant (6 litres) was analysed using an Agilent 1200 UHPLC coupled with an Agilent 6490 triple quadrupole MS (Agilent Technologies). Naringenin and hesperetin were separated in a Waters BEH C18 (100 × 2.1 mm, 1.7 micrometre particle size) at a flow rate of 0.6 ml/min using 6-5-min gradient 99% solvent A (water containing 0.1% formic acid) and 1% solvent B (acetonitrile containing 0.1% formic acid) (initially; 70% solvent A at 0 min; 2% solvent A at 5 min; 2% solvent A at 4 min; 55% solvent A at 2.5 min; 2% solvent A at 3 min; 2% solvent A at 4 min; 99% solvent A at 4.5 min followed by post-equilibration for 2 min). The MS was
operated in ESI-positive ionisation mode and multiple reaction monitoring (MRM) mode by monitoring quantifier and qualifier ions for both naringenin and hesperetin. MRM transitions were determined as 204/1/1440 (m/z) corresponding to caffeine, as 495/1/319-1 (m/z) corresponding to phenolphthalein–glucuronide and as 217/9/1379 (m/z) corresponding to potassium 4-nitrophenyl sulphate as quantifier ions. MRM transitions were determined as 305/1/153-1 (m/z) corresponding to hesperetin and 273/1/147-1 (m/z) corresponding to naringenin as qualifier ions. Concentrations of hesperetin and naringenin were then calculated on the basis of ratios of their integrated peak area for the quantifier ions to that of IS using two sets of eight-point calibration curves. Accuracy of the analysis was monitored by systematic counter-balancing between plasma samples and quality control samples spiked with known concentrations of hesperetin and naringenin. The method was validated for a linear calibration range of 0–313–802 µM for naringenin and 0–282–7–22 µM for hesperetin, respectively. In addition, limits of detection for naringenin and hesperetin were determined as 204·1/1440·<0·0313 µM and as 217·1/1379·<0·0282 µM, respectively.

Biochemical analysis

The blood samples collected in pre-chilled Li or heparin tubes were spun (4000 g; 10–15 min; 4°C) immediately after collection (within 5 min). Samples were also collected in serum separation tubes and allowed to stand for 30 min before centrifugation (1300 g; 10 min; 21°C). All samples were aliquoted and frozen at −80°C until analysis.

Plasma nitric oxide analysis. Plasma samples for measurement of total nitrosyl species (NOx) were aliquoted in 150-µl aliquots to avoid freeze-thawing of the samples for each measurement. Samples were defrosted just before the measurements took place (within 10 min) and were kept on ice throughout. Plasma samples (n 28) were analysed for nitrite, nitrate and other nitrosyl species (RNXO, including nitrosothiols, nitrosamines, iron-nitrosylhaemoglobin and nitrosohaemoglobin) by ozone-based chemiluminescence (model 88AM; Eco Physics) as previously described(53). In brief, for total NOx measurement (NO derived from nitrate, nitrite and RNXO), one aliquot of plasma was injected into an airtight microreaction vessel containing a solution of vanadium (III) chloride (50 mmoles) dissolved in 1 m-HCl, connected to a chemiluminescence analyser. For measurement of nitrite and other RXNO (i) one aliquot of plasma was injected in the same apparatus into glacial acetic solution containing 45 mmoles-potassium iodide and 10 mmoles-iodide, at 60°C, actively purged by inert He, which allowed the detection of NO from both nitrite and RXNO (but no nitrate). (ii) Subsequently, the plasma sample was treated with acidic sulphamidamide (1 m-HCl) to scavenge nitrite, before injection, allowing for quantification of RXNO alone. Nitrite levels in the plasma samples were determined by the difference between these two measurements (i and ii). Nitrate concentration was determined by subtracting nitrite + RXNO from total NOx. Samples used for calibration curves were prepared fresh every day and displayed consistent values across days.

Plasma baseline lipids and glucose. Plasma levels of total cholesterol, LDL-cholesterol, HDL-cholesterol, glucose and TAG were assayed on an ILAB 600 chemistry analyzer (Instrumentation Laboratory) using enzyme-based colourimetric tests supplied by Instrumentation Laboratory.

Power calculation and statistical analysis

Power calculations were performed for the primary end point – change in FMD response. Power was based on the intra-individual variability of the operator who performed the FMD analysis (5 % CV, SD=0·3%). Previous measures of variability in a control group estimated the standard deviation within subjects to be 2·3%. At 90 % power and 0·05 significance, the number of volunteers required to detect a difference of 1·5% in the response of matched pairs in a cross-over study was twenty-five. All statistical analyses were performed using SPSS Statistics 21 (IBM) package. FMD, blood pressure, plasma levels of nitric oxide species (nitrate, nitrite and RNXO) and plasma levels of flavonones were analysed using a two-way repeated measures ANOVA within subjects with time (0, 2, 5, 7 h) and treatment (C, OJ, FROJ, WO) as main factors. Post hoc and pair-wise comparisons were carried out using the Bonferroni correction for multiple comparisons. Significance was defined as P<0·05 (95 % CI) for all outcome measures, with P values represented in the figures as follows: *P<0·01–0·05, **P<0·001–0·01, ***P<0·001. Pharmacokinetic parameters were calculated as follows: (a) the maximum plasma concentration (Cmax) and (b) the time to reach the maximum plasma concentration (Tmax) were determined from the individual data obtained from each participant; (c) the area under the plasma concentration v. time curve (AUC) was calculated using the trapezoidal method. Multiple regression analysis was used to predict the value of FMD (dependent variable) based on the values of hesperetin and naringenin plasma levels (independent variables). Random allocation sequence was generated by a third party statistician using SAS version 9.1 (procedure plan and seed=122700). The randomised block design contained four blocks and nine randomised sequences within each block.

Results

Baseline characteristics and tolerance of intervention

The baseline characteristics of volunteers recruited were within the desired ranges, with TAG ranging from 0·8 to 3·2 mmol/l and total cholesterol from 6·0 to 8·0 mmol/l or/and BMI from 25 to 32 kg/m² (Table 3). All intervention beverages were well tolerated by all volunteers, as well as the high- and medium-fat meals administered throughout the study. No adverse events were reported.

Flavanone modulation of postprandial flow-mediated dilatation

A two-factor repeated-measures ANOVA for endothelium-dependent brachial artery vasodilation, measured FMD response, revealed a highly significant interaction between the interventions (C, OJ, FROJ, WO) and time of the day (0, 2, 5, 7 h) (F9,235 = 5·27, P<0·0001), as well as significant main effects of time of the day (F9,81 = 12·062, P<0·0001) and intervention (F3,81 = 2·78, P<0·05). At baseline (t=0 h), there were no significant differences in
Table 3. Baseline clinical characteristics of the study population
(Mean values with their standard errors)

<table>
<thead>
<tr>
<th>Baseline characteristics</th>
<th>Mean</th>
<th>SEM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>48</td>
<td>1</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>28.4</td>
<td>0.4</td>
</tr>
<tr>
<td>Total cholesterol (mmol/l)</td>
<td>5.6</td>
<td>0.2</td>
</tr>
<tr>
<td>HDL-cholesterol (mmol/l)</td>
<td>1.3</td>
<td>0.3</td>
</tr>
<tr>
<td>TAG (mmol/l)</td>
<td>1.5</td>
<td>0.1</td>
</tr>
<tr>
<td>Fasting glucose (mmol/l)</td>
<td>4.9</td>
<td>0.1</td>
</tr>
<tr>
<td>Hb (g/l)</td>
<td>149</td>
<td>1.0</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>124</td>
<td>1.7</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>74.9</td>
<td>1.5</td>
</tr>
<tr>
<td>Liver enzymes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alanine aminotransferase (IU/l)</td>
<td>42.1</td>
<td>2.1</td>
</tr>
<tr>
<td>γ-Glutamyltransferase (IU/l)</td>
<td>41.7</td>
<td>5.3</td>
</tr>
</tbody>
</table>

Fig. 2. Time course of postprandial flow-mediated dilatation (FMD) following consumption of flavanone beverages containing either 128.88 mg of flavanones (OJ, ——■——), 272.14 mg of flavanones (FROJ, ———□——) or a macronutrient- and micronutrient-matched control (—–○——) in middle-aged healthy men (n = 28). A high-fat breakfast (51 g of fat) was administered at t = 0 h, and a medium-fat lunch (30 g of fat) was administered at t = 5.5 h. Values are means, with their standard errors and analysed using a two-factor repeated-measures ANOVA with time and treatment as the two factors (significant main effects of time × treatment (P < 0.0001), treatment (P < 0.0001) and time (P < 0.05)). Post hoc analyses were conducted using Bonferroni’s multiple comparison test. * P < 0.05 OJ significantly different from control at the 7 h; †** P < 0.01 FROJ and WO significantly different from control at 7 h. ‡ Significant decrease in FMD response in relation to baseline levels for both control (at 2, 5 and 7 h; P < 0.0001, P < 0.05, P < 0.0001, respectively) and all three flavanone interventions (at 2 h; P < 0.05). OJ, orange juice; FROJ, flavanone-rich orange juice; WO, whole blended orange.

brachial artery FMD between visits, with the average baseline levels of FMD for the study population being 4.80 (SEM ± 0.03) FMD units. After 2 h of intake of the high-fat meal, a significant decrease in % FMD was detected for both control (P < 0.0001) and the three flavanone interventions (P < 0.05) (Fig. 2). In particular, in the control group, the % FMD decreased by 0.59 (SEM ± 0.17)% FMD after 2 h (P < 0.0001) and remained significantly suppressed 5 h (P < 0.005) and 7 h (P < 0.0001) after intake, relative to baseline levels. In contrast, all orange flavanone interventions resulted in a recovery in % FMD to that of baseline levels between 5 and 7 h (OJ: 4.51 (SEM ± 0.23)% FMD; FROJ: 4.74 (SEM ± 0.25)% FMD and WO: 4.75 (SEM ± 0.23)% FMD) (Fig. 2). At 5 h post intervention, there were no significant differences in % FMD between control and each of the flavanone interventions (OJ, FROJ, WO), whereas at 7 h (following intake of the medium-fat meal at 5.5 h) we observed a significantly higher % FMD for OJ (P < 0.005), FROJ (P < 0.001) and WO (P < 0.001) in comparison with control. There were no significant differences between the flavanone interventions at 7 h, with all three doses of flavanones administered (OJ: 128.8 mg; FROJ: 272.1 mg and WO: 452.7 mg) counteracting the deleterious effect of the double-meal challenge on % FMD response to a similar extent. Blood pressure was not significantly altered following consumption of any of the flavanone interventions, relative to baseline or to the control beverage (Table 4).

Modulation of plasma flavanones

Total flavanones, naringenin and hesperetin (including glucuronicides and sulphates), were not detected in the plasma of volunteers at baseline, indicating compliance to the 24-h low-flavanoid diet before the study visits. Flavanone metabolites were not detected in the circulation of individuals following intake of the control drink (Fig. 3). Significant increases in plasma levels of hesperetin metabolites were detected at 5 and 7 h (P < 0.0001) (Fig. 3(a)) and at 2, 5 and 7 h for naringenin metabolites (P < 0.0001) (Fig. 3(b)). The time to reach T_max for hesperetin and naringenin was not significantly different between treatments and coincided with the timeframe of FMD effects (Table 5). At 2, 5 and 7 h, plasma levels of naringenin were significantly higher following WO intake compared with OJ (P < 0.01) (Fig. 3(b)). Similarly, at 7 h, both FROJ and WO showed a trend towards higher plasma concentrations of hesperetin, relative to OJ (P < 0.1) (Fig. 3(a)). With respect to the C_max and AUC (0–24 h) for plasma hesperetin, both FROJ and WO were significantly higher than after OJ (P < 0.05), whereas for naringenin, both C_max and AUC were only significantly higher for WO in relation to OJ (P < 0.005) (Table 5). No significant differences in plasma flavanone levels were detected between FROJ and WO despite the different levels present in the treatment drinks. At 24 h, the levels of flavanones were not significantly different from baseline, indicating that the flavanone metabolites have been cleared from circulation (P = 0.13) (Fig. 3). A multivariate regression analysis, including both plasma naringenin and hesperetin, showed that hesperetin (P = 0.01) but not naringenin (P = 0.92), predicted changes in % FMD over the course of 0–7 h. Specifically, at 7 h, at the peak of FMD response, hesperetin significantly predicted the magnitude of FMD increase (r = 0.32, P = 0.005) following flavanone intake.

Modulation of plasma nitrite, nitrate and nitroso species including nitrosothiols, nitrosamines, iron-nitrosylaemoglobin and nitrosohaemoglobin

Levels of nitrate, nitrite and other RXNO species were determined in plasma at baseline and 2, 5 and 7 h after treatment (Fig. 4). Nitrite plasma levels are known to reflect more
Flavanones and endothelial function

Table 4. Acute postprandial effects of orange flavanone beverages on static blood pressure

<table>
<thead>
<tr>
<th>Blood pressure (mmHg)</th>
<th>Baseline</th>
<th>2h</th>
<th>5h</th>
<th>7h</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systolic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>125.5</td>
<td>1.9</td>
<td>126.7</td>
<td>1.9</td>
<td>126.7</td>
</tr>
<tr>
<td>OJ</td>
<td>124.8</td>
<td>1.5</td>
<td>125.7</td>
<td>1.2</td>
<td>125.72</td>
</tr>
<tr>
<td>FROJ</td>
<td>126.1</td>
<td>2.1</td>
<td>125.7</td>
<td>2.0</td>
<td>127.3</td>
</tr>
<tr>
<td>WO</td>
<td>126.1</td>
<td>1.6</td>
<td>125.1</td>
<td>1.4</td>
<td>124.8</td>
</tr>
<tr>
<td>Diastolic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>75.6</td>
<td>1.6</td>
<td>71.5</td>
<td>1.4</td>
<td>74.6</td>
</tr>
<tr>
<td>OJ</td>
<td>74.9</td>
<td>1.5</td>
<td>70.1</td>
<td>1.2</td>
<td>73.7</td>
</tr>
<tr>
<td>FROJ</td>
<td>75.5</td>
<td>1.5</td>
<td>70.9</td>
<td>1.6</td>
<td>74.6</td>
</tr>
<tr>
<td>WO</td>
<td>76.0</td>
<td>1.6</td>
<td>69.9</td>
<td>1.4</td>
<td>73.9</td>
</tr>
</tbody>
</table>

OJ, Tropicana pure premium orange juice without pulp; FROJ, flavanone-rich orange juice: Tropicana pure premium orange juice with added orange pomace; WO, juice made from lightly blended fresh whole orange.

Fig. 3. Plasma flavanone profile following postprandial consumption of flavanone beverages containing either 128.8 mg of flavanones (OJ, ), 452.14 mg of flavanones (FROJ, ), or a macronutrient- and micronutrient-matched control ( ) in middle-aged healthy men (n=20). (a) Hesperetin, (b) naringenin. Values are means, with their standard errors and analysed using a two-factor repeated-measures ANOVA with time and treatment as the two factors (significant main effects of time × treatment (P<0.0001), time (P<0.0001) and treatment (P<0.0001). Post hoc analyses were conducted using Bonferroni’s multiple comparison test. Hesperetin levels are significantly higher in all treatments in comparison with control at 5 and 7 h (±0.000<P<0.002), whereas naringenin levels are significantly higher in all treatments in comparison with control at 2, 5 and 7 h (±0.000<P<0.003). Levels of plasma naringenin are significantly higher in OJ in comparison with WO. **P<0.01, ***P<0.001. § Levels of plasma hesperetin in FROJ and WO show a trend towards higher values than OJ (P<0.1). OJ, orange juice; FROJ, flavanone-rich orange juice; WO, whole blended orange.

Fig. 4. Changes in plasma nitrite, nitrate and other RXNO species. The average levels of plasma nitrite, nitrate and other RXNO at baseline were 32.1 µmol/l, 68.3 nmol/l and 0.4 nmol/l, respectively, which is in agreement with the values reported in the literature. A significant decrease in plasma nitrite levels was observed at 2, 5 and 7 h for all the interventions, including control (P<0.0001) (Fig. 4(b)). In contrast, plasma nitrite levels remained constant up to 7 h after treatment (not significantly different from baseline) following OJ, FROJ and WO intake, whereas the control group nitrite levels decreased significantly (P<0.0001) (Fig. 4(a)). No significant changes were detected in RXNO levels in plasma (NS) (Fig. 4(c)).

Discussion

Considerable evidence suggests that dysregulation of endothelial function in the postprandial state is an important contributing factor for CVD risk, whereas intakes of flavonoid-polyphenol-rich foods such as cocoa, tea and berries have been shown to exert positive effects on vascular function. In support of this, clinical trial data have indicated that intakes of such foods/beverages may lower CVD disease risk, at least partially, through their actions in mitigating fed-state metabolic and vascular disturbances. In the present study, we showed that intervention with orange flavanones, both as juice and whole orange in homogenised form, counteracts impairments in vascular function evoked by a sequential double-meal challenge, which reflects a regular eating pattern and a typical dietary intake in the population. Each flavanone intervention tested was effective in reversing vascular impairments, to a physiologically similar degree, despite them containing different levels of flavanone metabolites. No changes in blood pressure were observed. The rescue of transient impairments in vascular function, as assessed using brachial artery FMD, coincided with the peak of flavanone metabolites (total sulphates and glucuronides) in circulation (7 h) and with sustained levels of plasma nitrite, the latter of which was significantly reduced by the double-meal challenge. Thus, our data support the concept that the observed postprandial vascular benefits may be linked to the actions of circulating flavanone metabolites on NO bioavailability.
Table 5. Pharmacokinetics of the major plasma flavanones, naringenin and hesperetin, after consumption of beverages containing either 128.88 mg (OJ), 272.14 mg (FROJ) or 452.80 mg (WO) of total orange flavanones in healthy middle-aged men (Mean values with their standard errors; n=20)

<table>
<thead>
<tr>
<th>Flavanones</th>
<th>C&lt;sub&gt;max&lt;/sub&gt; (μm)</th>
<th>T&lt;sub&gt;max&lt;/sub&gt; (h)</th>
<th>AUC (0–24 h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hesperetin</td>
<td>Mean 0.10 ± 0.00</td>
<td>Mean 0.10 ± 0.1</td>
<td>Mean 0.07 ± 0.9</td>
</tr>
<tr>
<td>Naringenin</td>
<td>Mean 0.05 ± 0.00</td>
<td>Mean 0.2 ± 0.0</td>
<td>Mean 0.1 ± 0.0</td>
</tr>
</tbody>
</table>

OJ, Tropicana pure premium orange juice without pulp; FROJ, flavanone-rich orange juice: Tropicana pure premium orange juice with added orange pomace; WO, juice made from lightly blended fresh whole orange.

* P<0.05 significant difference in C<sub>max</sub>/AUC in WO or FROJ in relation to OJ.
† P=0.058 trend in AUC in FROJ in relation to OJ. No significant differences in T<sub>max</sub> were detected between treatments.
Our findings are consistent with previous randomised controlled trial (RCT) data sets indicating that cocoa flavanols partially counteract the decrease in FMD following high-fat meal loading\(^{32}\). Furthermore, pure quercetin has also been shown to ameliorate postprandial FMD following maltose overload\(^{35}\). To our knowledge, this is the first set of data indicating that citrus flavanones are also capable of attenuating postprandial impairments in endothelial function following a sequential high-medium-fat double meal in individuals displaying mild cardiometabolic risk factors. Furthermore, and in support of our findings, previous studies conducted in the fasted state report that chronic interventions with flavanones in at-risk groups (e.g. hypertensive, overweight or the metabolic syndrome patients) induce positive effects on blood pressure and endothelial function (FMD)\(^{45,46,55}\) and improvements in microvascular reactivity\(^{45}\). Most importantly, in the present study, no dose-dependent effects on brachial artery FMD were observed, despite the interventions containing different amounts of flavanones (W0: 3.5±0.1). This may indicate that at these intake levels a threshold plateau may be reached, similar to what has been shown previously with other flavonoid-rich interventions\(^{22}\). It also further suggests that lower doses of flavanones (approximately 130 mg) can be efficacious at modulating postprandial endothelial function. No changes in blood pressure were observed in the present study, which is in agreement with previous human intervention trials reporting modulation of blood pressure only after chronic interventions with flavonoid-rich foods, but not in an acute manner\(^{27,31}\).

We observed concurrent modulation of FMD, nitrite and circulating flavanone metabolites (total sulphates and glucuronides), suggesting that the latter may be linked to NO availability and subsequent improvements in vascular function, although we cannot establish a causal relationship at this time. Specifically, both naringenin and hesperetin metabolite peak plasma levels for all three interventions occurred at approximately 7 h, which coincided with significant improvements in endothelial function (at 7 h) and sustained levels of circulating nitrite after flavanone interventions in comparison with control. Plasma levels of flavanone metabolites peaked slightly later than that previously reported (4–6 h)\(^{45,56,57}\), most likely due to the concomitant intake of fat, which is thought to interfere with flavonoid absorption\(^{58}\). On the other hand, no significant differences in time of absorption were detected between the flavanone treatment groups (peak occurs at approximately 7 h for all three treatments).

In support of the link between flavanone intake and human vascular function, we observed that when low or no levels of flavanone metabolites are detected in circulation (e.g. 2 h), no differences in postprandial brachial FMD are observed between control and flavanone-rich beverages. Further, multiple regression analyses suggest that mainly hesperetin metabolites seem to predict significantly the magnitude of changes in FMD (\(r=0.52, P=0.005\)), suggesting an important role of this flavanone in the effects observed. This is corroborated by previous studies showing that pure hesperidin can trigger both acute and chronic improvements in vascular function in humans\(^{45,46}\). It is important to further note that only the sulphated and glucuronidated portion of the flavanone metabolites were quantified in our study, and these are likely to account for a fraction (approximately 16%) of the total flavanone metabolites absorbed\(^{59}\). As such, we anticipate that gut-derived phenolic compounds might also contribute to the improvements in endothelial function observed. This is supported by our observation that hesperetin metabolites can only significantly predict a small percentage (approximately 30%) of the FMD response observed; therefore, it is likely that stronger correlations might be apparent once gut-derived small phenolic metabolites are taken into consideration; however, such extensive analysis was outside of the scope of our study.

Our study also indicates that the impairment in postprandial FMD induced by the sequential high-fat meal might be linked to decreases in circulating levels of NO species, particularly nitrite and nitrate. Although the precise mechanisms underlying postprandial endothelium impairments are not established, mechanistic animal studies suggest a role for NO signalling, showing, for example, that endothelial dysfunction induced by fat intake also results in decreases in NO production\(^{50–62}\). Importantly, the flavanone interventions only prevented the decrease in nitrite, but not nitrate. Numerous evidence suggest that nitrite reflects more accurately endogenous NO production in humans, with an estimate of 70–80% of plasma nitrite deriving from eNOS activity\(^{46,60}\) and also better reflects the degree of endothelial dysfunction in humans\(^{65}\). In agreement with our data, previous human clinical data suggest an ability of some flavonoid-rich foods to modulate NO bioavailability\(^{22,24,35,57}\). In particular, cocoa flavanols-induced improvements in FMD have been causally linked to NO production in humans\(^{24}\). More recently, Bondonno et al.\(^{57}\), also showed that apples containing (+) epicatechin and quercetin increased levels of nitrite along with FMD response after 2 h of intake. In addition, and in agreement with the present data, both pure (+) epicatechin and quercetin were shown to specifically increase plasma nitrite, but not nitrate in healthy humans\(^{55}\). Supporting in vitro mechanistic studies (in endothelial cells) have demonstrated that flavanone hesperitin and some of its in vitro metabolites (e.g. 7-O-β-D-glucuronide) can stimulate NO production via activation/ expression of eNOS\(^{46,60}\) or by decreasing NO degradation through inhibition of NADPH\(^{67}\), and these are possible mechanistic pathways by which flavanone metabolites might modulate postprandial FMD. Although the specific modulation of nitrite by flavanone-containing interventions is an interesting observation in the present study, the interpretation of the temporal dynamics (time course) of flavanone appearance in plasma and levels of plasma nitrite is not straightforward with regard to explaining the effects of nitrite on FMD. This seems to suggest that the impact of flavanone metabolites on FMD response cannot be explained completely by modulation of nitrite (as a measure of NO). As the present study was not designed (or powered) to detect changes in NO species, we are limited in our ability to establish a clear-cut link between FMD modulation and NO at this time. However, we believe this preliminary data are very novel and valuable for future, more mechanism-focused, human RCT.

Interestingly, FROJ intake resulted in similar levels of plasma flavanones to W0, despite lower initial concentrations, which might be related to characteristics of the food matrix itself, such as viscosity, which is known to influence the bioavailability of
polyphenols. It is possible that the reduced particle size of pomace in FROJ aided the release of polyphenols from the fibre matrix, making these more accessible for gut microbiota metabolism. It is known that dietary fibre can physically trap polyphenols within the fibre matrix in the fruit tissue, reducing the accessibility to enzymes and the gut microbiota. On the other hand, the rate of release of polyphenols from fibrous particles is inversely proportional to the fibre particle size, therefore, by reducing particle size in the pomace, we are likely to increase the bioavailability of flavonanes in FROJ. In order to confirm that this is the case, future studies should focus on measuring accurately total urine excretion (e.g. over a 24h period). Nonetheless, our study seems to suggest that particle size reduction of fibre-rich orange pomace and the re-introduction of this product into orange juice might be an effective strategy to increase the bioavailability of polyphenols in vivo. Importantly, the increased bioavailability of flavonanes after FROJ intake did not enhance significantly postprandial FMD in comparison with lower flavanone-containing OJ, again suggesting that perhaps a certain level of flavonane metabolites is necessary in circulation to trigger postprandial FMD improvements, but further increases in flavonane levels may not produce additional benefits.

One of the limitations in the design of the present study is related to the composition of the control intervention, which did not take into account the levels of ascorbic acid present in the citrus beverages. Clinical studies suggest that doses up to 500 mg of vitamin C do not impact on biomarkers of endothelial function. More specifically, it has been shown in a recent stratified meta-analysis that doses ranging from 90 to 500 mg of ascorbic acid do not produce improvements in endothelial function, both acutely or chronically, especially in populations with normal vitamin C status. Furthermore, previous studies reporting acute beneficial effects of ascorbic acid on endothelium-dependent vasodilation (within 2-4h of intake) delivered doses of at least 2000 mg, and in many cases positive outcomes were achieved by delivering ascorbic acid intravenously, resulting in supra-physiological plasma levels of vitamin C, which cannot be achieved by oral ingestion. As the levels of vitamin C in the present study were approximately 80-120 mg, we are confident that these can be considered negligible with respect to acute effects on endothelial function, as measured by FMD. Therefore, despite these limitations, we can safely argue that our conclusions are reasonable when attributing the FMD response to circulating flavanone metabolites (at 7h post intake) and that our data are relevant in furthering the understanding of the impact of flavonoid-rich foods/beverages on postprandial endothelial function.

In summary, our results suggest that acute intake of a beverage containing at least 128 mg of flavonanes can be an effective dietary strategy to blunt the acute transient impairment in endothelial function induced by a sequential double meal that reflects a typical intake in the population. Although we cannot draw firm conclusions regarding the mechanisms by which flavonanes elicit vascular responses, our results suggest that these might be linked to an ability of flavonane metabolites to sustain basal circulating NO levels. Collectively, these observations have important implications, considering that most individuals spend the majority of the day in the postprandial state, and such temporary vascular changes repeated on a daily basis can critically impact on long-term vascular health and overall chronic disease risk.

Acknowledgements

This work was supported by PepsiCo Inc. (PEP-1122) and is greatly appreciated. The views expressed in this manuscript are those of the authors and do not necessarily reflect the position or policy of PepsiCo Inc.

C. R.: coordinated and conducted the study, undertook all FMD measurements, performed data analysis and wrote the manuscript; H. D.: coordinated and conducted the study; C. S.: designed and coordinated the study and wrote the manuscript; L. H.: designed the study; R. L. B.: conducted study drinks analysis; M. B., Y. H.: conducted plasma flavanone analysis; G. C.: conducted NO species measurements and analysis; J. A. L.: co-investigated the study and was involved in experimental design; J. P. E. S.: principal investigator, involved in the experimental design and writing of the manuscript. All authors reviewed the manuscript.

C. S. works as a Senior Scientist at PepsiCo Inc., L. H. works as a Senior Director at Global R&D Nutrition at PepsiCo Inc., R. L. B., M. B. and Y. H. work as Principle Scientists at PepsiCo Inc. The other authors declare no conflicts of interest.

References


